key: cord-0820295-gu81sgbm
authors: Patel, Suyog; Parikh, Charmy; Verma, Deepak; Sundararajan, Ramaswamy; Agrawal, Upasana; Bheemisetty, Niharika; Akku, Radhika; Sánchez‐Velazco, Diana; Waleed, Madeeha Subhan
title: Bowel ischemia in COVID‐19: A systematic review
date: 2021-10-10
journal: Int J Clin Pract
DOI: 10.1111/ijcp.14930
sha: b06ba598df16320d14598450efef5ac46b93acfb
doc_id: 820295
cord_uid: gu81sgbm

BACKGROUND: Gastrointestinal complications of COVID‐19 have been reported over the last year. One such manifestation is bowel ischaemia. This study thus aims to provide a more holistic review of our current understanding of COVID‐19‐induced bowel ischaemia. METHOD AND RESULTS: A meticulous search was performed using different keywords in PubMed and Google Scholar. Fifty‐two articles were included in our study after applying inclusion and exclusion criteria and performing the qualitative assessment of the studies. A total of 25 702 patients were included in our study after the completion of the qualitative assessment. DISCUSSION: The common symptoms of GIT in COVID‐19 patients are as diarrhoea, vomiting, nausea and abdominal pain. The mechanism of bowel ischaemia is associated with the formation of emboli which is related to COVID‐19’s high affinity for angiotensin‐converting enzyme‐2 on enterocytes, affecting the superior mesenteric vessels. Clinically, patients present with abdominal pain and vomiting. CT angiography of the abdomen and pelvis showed acute intestinal ischaemia (mesenteric). Management is usually initiated with gastric decompression, fluid resuscitation, and haemodynamic support. Surgical intervention is also sought. CONCLUSION: Intestinal ischaemia presenting in patients with COVID‐19 has to be considered when symptoms of severe abdominal pain are present. More research and guidelines are required to triage patients with COVID‐19 to suspect intestinal ischaemia and to help in diagnosis and management.

A standardised data abstraction form was adopted to extract the data from databases. The authors DV, SP and RA extracted the data manually. Any difference in opinion was resolved through mutual discussion among the authors. The following information was extracted: authors, year of publication, no of cases or participants in the study, study design, laboratory findings and treatment procedure adopted for the management, complication and outcome in the patients following the treatment.

An initial search of the databases yielded 180 826 articles using advanced search strategies which included Medical Subjects Heading

[MeSH] as well. The articles were then screened by applying eligibility criteria as discussed above which left us with 92 articles and 180 734 articles were excluded. Ninety-two articles were screened

• We gathered information with the help of an electronic search using PubMed and Google Scholar by using keywords either in combination or alone.

• Keywords used were "COVID-19," "Bowel ischemia," "Mesenteric ischemia," and "pathophysiology,"

"Management," "Sequelae."

• Articles went through our inclusion and exclusion criteria mentioned in the methods section to decide whether to include them in our review.

• Clinical Appraisal tools were later applied to each of the articles by the authors for quality analysis.

Message for the clinic • We intend to provide an insight to the clinician so that an early diagnosis of bowel ischaemia is made and none of the cases are missed.

• We have included even very rare presentations of bowel ischaemia and methods of their diagnosis to guide the clinician in their management.

• Bowel ischaemia should not be taken lightly as it has a very high mortality rate. It requires the immediate attention of the clinician while managing the patient of COVID-19. and 32 articles were removed because of irrelevant or insufficient information or not having a full-text article or abstract. Sixty articles were then assessed for eligibility.

The eligibility was determined by the use of various critical appraisal tools as mentioned above. Fifty-two articles qualified for the critical appraisal assessment and were included in our study. Eight articles were excluded for not qualifying the critical appraisal assessment. Figure 1 below shows the PRISMA flow diagram mentioning the result of our study. 6 A total of 25 702 patients were included in our study from 10 observational studies, three systematic reviews, meta-analysis, and 24 case reports. Fever was the most predominant presenting complaint reported. Most of the studies reported the presence of acute abdomen, nausea, loss of appetite, diarrhoea along with sore throat, cough, confusion and sepsis in severely ill patients.

All the cases included in our study were laboratory-confirmed SARS-CoV-2 positive. We tried to explore the diagnostic findings suggesting bowel ischaemia. Most of the cases did not report any laboratory findings supporting the diagnosis of bowel ischaemia. Some studies reported elevation of D-dimer and lactate dehydrogenase. below summarises the presenting complaints and laboratory findings in various studies.

Patients infected with COVID-19 have shown GI symptoms (2%-10%); however, those numbers, in reality, appear to be much higher. 7 Hypercoagulability can also be a result of the circulating microvesicles that can originate from platelets, monocytes or neutrophil extracellular traps released from activated neutrophils. 22 Lastly, patients with severe COVID-19 pneumonia might require vasopressors like norepinephrine and high-dose epinephrine to treat shock and haemodynamic instability. The resulting vasoconstriction and decreased mesenteric blood circulation can lead to nonocclusive mesenteric ischaemia. 26 Figure 2 below summarises the mechanism involved in AMI. Severe COVID-19 pneumonia should raise concern for a hypercoagulable state. Diagnosing and treating such patients early in the disease course has shown better outcomes

The SARS-CoV-2 virus has been found to cause pneumonia as well as a variety of other symptoms in the gastrointestinal, cardiovascular, and nervous systems as part of a multi-inflammatory syndrome, which is becoming more widely recognized as a part of the disease spectrum. Coagulopathy associated with COVID-19 has become a major contributor to high mortality and morbidity, with ischemic bowel disease being one of the outcomes. 27 Because clinical factors are ineffective at predicting or suspecting coagulopathy and associated consequences, it is critical to be aware of imaging symptoms of COVID-19 coagulopathy sequelae. 28 One of the suggested mechanisms for paralytic ileus/small bowel obstruction is through the inflammatory process from the virus entry into the small intestine and leading to micro thrombosis of the microcirculation. 32 Studies have shown that in patients infected with coronavirus gastrointestinal involvement is seen in at least twothirds of patients. Coagulation abnormalities and elevated D-dimer levels were noted in patients with COVID-19 and are related to a poor clinical outcome and a very high inpatient mortality rate. 33 A case report in a COVID-19-positive patient who had patent mesenteric vessels associated with catastrophic bowel necrosis suggested that it can be caused by microvascular thrombosis and inflammation.

It is considered as one of the proposed mechanisms in such patients known to have hypercoagulability. 34 Another case report in a patient with COVID-19 has shown how superior mesenteric thrombosis can present as intestinal obstruction from congenital adhesion, which is a rare surgical condition. This patient had an acute presentation from small bowel stricture which can be one of the sequelae secondary to bowel ischaemia. 35 Cases have been reported in which COVID-19 led to gastric wall perforation, caecal perforation and sigmoid diverticulitis with perforation which were treated conservatively and surgically. 36 

It has been documented that COVID-19 leads AMI. 33, 39 This has often been attributed to the hypercoagulable state that the novel coronavirus puts the patient's body in, which eventually leads to bowel ischaemia. 40 The importance of early diagnosis and prevention cannot be stated enough. The cornerstone of management of such an acute emergency is the immediate restoration of blood flow, and removal of any necrotic bowel. 41, 42 This is an evolving topic and there are no clear guidelines specific to COVID-19-related bowel ischaemia when it comes to management. It is in the interest of healthcare providers to aid in the prevention of such severe complications as bowel ischaemia. Based on the understanding of the increased incidence of thrombotic events F I G U R E 3 Co-relation of AGI with in patients with COVID-19, the use of prophylaxis as well as out and out anticoagulation strategies have been tried and tested with favourable outcomes. 43 Screening with CT imaging and prothrombotic workup also plays a role in the early diagnosis of bowel ischaemia.

Supportive and conservative therapy includes gastric decompression, fluid resuscitation, and hemodynamic support. 44, 45 Also, early diagnosis and systemic thrombolysis have been shown to produce better outcomes in terms of bowel salvage. 44, 45 In terms of surgical interventions, exploratory laparotomy followed by bowel resection was often sought because of the acute presentation of the case. Another treatment modality involves an endovascular approach such as superior mesenteric artery (SMA) thrombectomy with stent repair, or catheter-directed thrombolysis with thrombus aspiration. 45 Tocilizumab, a monoclonal antibody acting against the IL-6 receptor, has been used to treat hospitalised patients with severe COVID-19. 46 Shaikh DH et al mentions its use as an infusion, in COVID-19-induced small bowel ischaemia, after a patient underwent surgical intervention. Good recovery was seen. In this case, it was also noted that convalescent plasma therapy along with tocilizumab infusion, was used post-op. 47 But, symptomatic and supportive care is the mainstay of therapy. In a general sense as well, more studies will help throw visibility on this unique but drastic complication of COVID-19 so that better treatment modalities may be identified. Table 3 presented below outlines the various management strategies involved in the treatment of bowel ischaemia secondary to COVID-19.

This study is not without its limitations. COVID-19 is still very much under investigation. Currently, there is not enough material for us to confidently establish causation and management of COVID-19induced bowel ischaemia. Another point to note is that this is a retrospective study. While we are able to identify cases where AMI has occurred, we are unable to identify the baseline exposure status of such patients. Without this, we cannot point out the factors that lead to patients developing mesenteric ischaemia. Prospective studies in this direction will go a long way in understanding this complication.

In addition, the pathophysiology of COVID-19-induced bowel ischaemia is not well-established. This is an important area of research that requires further exploration to help define this mechanism.

Acute mesenteric ischemia does seem to be a rare complication of COVID-19. This review article underscores the importance of placing AMI in the workup of such a patient with COVID-19 presenting with manifestations of the gut, most commonly acute abdomen. Elevated lactate, LDH, and d-dimer levels can be considered while assessing a patient of COVID-19 with abdominal pain for mesenteric ischaemia.

Ultimately, Computed Tomography of the abdomen helps clinch the diagnosis. However, more prospective studies are required to assess the laboratory diagnostics to help suspect as well as confirm bowel ischaemia in a patient with COVID-19. Immediate intervention may help provide better outcomes. It is important to acknowledge that adequate thrombolysis and hemodynamic support should be implemented as they may help maintain homeostasis thereby aiding in early diagnosis or even preventing this complication.

No author has any conflicts of interest.

Data used in this study were a re-analysis of existing data, which are openly available at locations cited in the reference section. This data are publicly available to everyone at Pubmed Central [https://pubmed.ncbi.nlm.nih.gov/] and Google scholar [https://schol ar.google.

com/]. No datasets were generated or analysed during this study.

Understanding the mosaic of COVID-19: a review of the ongoing crisis

The hypercoagulable state in COVID-19: incidence, pathophysiology, and management

The looming storm: blood and cytokines in COVID-19

COVID-19 presenting as acute limb ischaemia

COVID-19 presenting as acute limb ischemia

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Clinical characteristics of coronavirus disease 2019 in China

Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study

Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from the Hong Kong cohort and systematic review and meta-analysis

AGA institute rapid review of the GI and liver manifestations of COVID-19, meta-analysis of international data, and recommendations for the consultative management of patients with COVID-19

Digestive symptoms in COVID-19 patients with mild disease severity: clinical presentation, stool viral RNA testing, and outcomes

Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis

Severe COVID-19 initially presenting as mesenteric adenopathy

Pneumatosis intestinalis due to COVID-19 infection in kidney transplant recipient: a case report

Gastrointestinal symptoms are associated with severity of coronavirus disease 2019

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

The first case of 2019 novel coronavirus pneumonia imported into Korea from Wuhan, China: implication for infection prevention and control measures

Detection of novel coronavirus by RT-PCR in stool specimen from asymptomatic child

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan

Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD Expert Panel Consensus Statement

COVID-19 and acute mesenteric ischemia: a review of literature

Acute mesenteric thrombosis in two patients with COVID-19. Two cases report and literature review

Acute mesenteric ischemia in severe coronavirus-19 (COVID-19): possible mechanisms and diagnostic pathway

Small bowel ischemia and SARS-CoV-2 infection: an underdiagnosed distinct clinical entity

Case report: ischemic colitis in severe COVID-19 pneumonia: an unforeseen gastrointestinal complication

Gangrenous bowel ischemia-a complication of COVID-19: a case report

COVID-19 induced mesenteric venous infarction

Abdominal imaging findings in patients with SARS-CoV-2 infection: a scoping review

Multidetector computed tomography of mesenteric ischaemia

ACR appropriateness criteria® imaging of mesenteric ischemia

Acute abdomen in a 54-year-old COVID-19 patient: a case report

Superior mesenteric artery thrombosis and acute intestinal ischemia as a consequence of COVID-19 infection

Bowel necrosis in the setting of COVID-19

A peculiar case of small bowel stricture in a corona virus disease 2019 patient with congenital adhesion of small bowel stricture in a corona virus disease 2019 patient with congenital adhesion band and superior mesenteric vein hrombosis

Gastrointestinal perforation secondary to COVID-19

Colonic gangrene: a sequela of coronavirus disease 2019

Acute gastrointestinal injury and feeding intolerance as prognostic factors in critically ill COVID-19 patients

A rare case of acute mesenteric ischemia in the setting of COVID-19 infection

Acute superior mesenteric artery thrombosis seven days after discharge for novel coronavirus pneumonia (NCP)

Rare case of COVID-19 presenting as acute abdomen and sepsis

Gastrointestinal manifestations in COVID-19

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Staged acute mesenteric and peripheral ischemia treatment in COVID-19 patient: case report

Early detection and successful management of acute mesenteric ischaemia in symptomatic COVID-19 patient

Effectiveness of tocilizumab in patients hospitalized with COVID-19: a follow-up of the CORIMUNO-TOCI-1 randomized clinical trial

Colonic ileus, distension, and ischemia due to COVID-19-related colitis: a case report and literature review

Bowel ischaemia in COVID-19: A systematic review